Read the inaugural issue of Pharmacology Research & Perspectives

53417-PRP-journalWe are pleased to announce that Pharmacology Research & Perspectives has now published its inaugural issue. Pharmacology Research & Perspectives is a new journal from the British Pharmacological Society (BPS) and the American Society for Pharmacology & Experimental Therapeutics (ASPET) and promotes research in all areas of pharmacology.   
 
The editor’s choice articles from the inaugural issue are:  
  
purple_lock_openGreen fluorescent protein fused to peptide agonists of two dissimilar G protein-coupled receptors: novel ligands of the bradykinin B2 (rhodopsin family) receptor and parathyroid hormone PTH1 (secretin family) receptor
Xavier Charest-Morin, Jean-Philippe Fortin, Marie-Thérèse Bawolak, Robert Lodge and François Marceau    

purple_lock_openEffects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo
Seth C. Hopkins, Una C. Campbell, Michele L. R. Heffernan, Kerry L. Spear, Ross D. Jeggo, David C. Spanswick, Mark A. Varney and Thomas H. Large    

purple_lock_open Cilostazol prevents retinal ischemic damage partly via inhibition of tumor necrosis factor-?-induced nuclear factor-kappa B/activator protein-1 signaling pathway
Fumiya Ishizuka, Masamitsu Shimazawa, Yusuke Egashira, Hiromi Ogishima, Shinsuke Nakamura, Kazuhiro Tsuruma and Hideaki Hara
 

Read inaugural issue

 Pharmacology Research & Perspectives invites authors to submit research articles and invites submission of several types of special articles. These are:
1. Target validation – publication of negative findings including preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development
2. Drug discovery reviews – strategy, hypotheses and data resulting in a successful therapeutic drug
3. Frontiers in translational medicine – drug and target validation for an unmet therapeutic need
4. Pharmacological hypotheses – reviews that are oriented to inform a novel hypothesis

All articles are published under a Creative Commons License and comply with all open access mandates.

PRP2

Pharmacology Research & Perspectives Supports the Publication of Negative Findings

prp_cover_final.inddTwo leading pharmacology societies, the British Pharmacological Society (BPS) and the American Society for Pharmacology and Experimental Therapeutics (ASPET), have announced their support for the publication of negative findings from early clinical trials. Their jointly published journal, Pharmacology Research & Perspectives, is at the same time launching an efficient and timely means for researchers to publish negative findings in two important areas: preclinical papers that show a hypothesis to be incorrect, and papers on drugs that have failed in early clinical development that can inform whether further drug development in warranted.

Professor Phil Routledge, BPS President, comments: “It is ethically correct for pharmacologists working in academia, industry and the health services to publish negative findings. Openness not only ensures that the research community is collectively making the best possible use of resources, but also that clinical trial volunteers are not unnecessarily exposed to likely ineffective or potentially unsafe treatments when evidence may already suggest that the drug target in question is flawed.”

Both BPS and ASPET are committed to the view that new opportunities for publishing negative findings are needed, in order to avoid unnecessary duplication of research and waste of resources [1]. It has been well-documented that it is difficult for authors to find journals prepared to publish negative findings [2]. In addition, once a trial shows negative results, resources within an organization may be reallocated so there may not be the opportunity to produce and submit a scientific paper subsequently.

Dr Mike Curtis, BPS Fellow and Editor-in-Chief of Pharmacology Research & Perspectives, adds: “Historically, negative findings have tended to remain unpublished. As an author I found that journal referees often rejected papers on the grounds that the findings were negative. Now, as an Editor-in-Chief, I’m conscious that those who ignore history are condemned to repeat the mistakes of the past. When there is no record of history then it is inevitable that others will waste time and resources in unwitting replication of failed programmes.”

Dr James Barrett, Chair of ASPET’s Board of Publications Trustees, also comments: “The failure to publish preclinical and clinical findings that do not support a hypothesis or the therapeutic value of a drug because they are ‘negative’ and should remain generally unavailable may not be beneficial to progress. If such studies are based on appropriate methodology and conducted well, they can add valuable information that can provide a positive direction and momentum to both basic and clinical research. Adopting this policy places Pharmacology Research & Perspectives in a unique position to advance both preclinical and clinical research.

BPS Honorary Fellow, Professor Sir Michael Rawlins observes: “I have previously stated that I believe that all negative and positive trials should be in the public domain, so I welcome this move to ensure that negative findings related to early clinical trials can be submitted for publication.”

“The announcement from BPS and ASPET is very welcome international leadership from societies who want to ensure clinical trial information is published. The results of around half of all trials are not published – this information is kept from doctors, researchers and regulators; resources are wasted repeating research that has been done and participants in further clinical trials are misled. I hope more organisations will follow BPS and ASPET’s lead and set out what they can do to ensure more clinical trials report their results,” added Síle Lane, Sense About Science, one of the founding organisations of the AllTrials campaign.

Full information about the call for papers on target validation is available from the Pharmacology Research & Perspectives  website.


[1] Hayes A, Hunter J. Why is publication of negative clinical trial data important? Brit J Pharmacol.2010;167: 1395–7.

[2] Sterne JAC, Eggers M, Moher D. Addressing reporting biases. Cochrane Handbook for Systematic Reviews of Interventions.

Pharmacology Research & Perspectives – Editorial Board Appointed

prp_cover_final.inddPharmacology Research &Perspectives’ editorial board has now been appointed to lead the publication in its infancy alongside Editor-in-Chief Mike Curtis and Deputy Editor Darrell Abernethy.  The new board members are listed in full below.

The journal launched at Experimental Biology 2013 and the first articles will be published shortly. The editors have appointed a strong team to help to shape the strategic direction of the journal. The consulting editors and the remainder of the editorial board will work closely with the editors to ensure a rigorous peer review processs for the journal.

Authors are invited to submit their articles using the online submission site.

Editor-in-Chief
Michael J. Curtis, London, UK

Deputy Editor
Darrell R. Abernethy, Maryland, USA

Consulting Editors
Thomas Brand, Imperial College, UK
John Challiss, University of Leicester, UK
Mark Connor, Macquarie University, Sydney, Australia
Josephine Egan, National Institute of Aging, Baltimore, USA
Alison Gurney, The University of Manchester, UK
Paul Insel, University of California San Diego, USA
Donald Mager, University at Buffalo, New York, USA
Andrew McLachlan, University of Sydney, Australia
Michael Randall, University of Nottingham, UK

Editorial Board
Karin Aubrey, University of Sydney, Australia
Chris Bailey, University of Bath, UK
Wah Chin Boon, The Florey Institute of Neuroscience and Mental Health, Australia
Elizabeth Cartwright, The University of Manchester, UK
Thomas Chang, The University of British Columbia, Canada
Ying Chen, University of Surrey, UK
Mark Cunningham, Newcastle University, UK
Margaret Cunningham, University of Bristol, UK
Susan Currie, University of Strathclyde, UK
Yvonne Dempsie, Glasgow Caledonian University, UK
Robert Drummond, University of Strathclyde, UK
Ryoichi Fujiwara, Kitasato University, Japan
Jacob George, University of Dundee, UK
Daniel Gonzalez, University of North Carolina at Chapel Hill, USA
Natasha Grimsbey, University of Auckland, New Zealand
Subash Gupta, University of Mississippi Medical Center, USA
Ioannis Haralambopoulos, University of Crete, Greece
Liz Hardaker, Novartis, UK
Anders Haunso, Merck Research Laboratories, USA
Nick Holliday, University of Nottingham, UK
Dana Hutchinson, Monash University, Australia
Jee Hyan Kim, University of Melbourne, Australia
Manoj Lalu, University of Ottawa, Canada
Emma Lane, Cardiff University, UK
Robert Lane, Monash University, Australia
Derek Lang, Cardiff University, UK
Anastassios Lymperopoulos, Nova Southeastern University, USA
Oliver Mace, Heptare Therapeutics, UK
Leanne Mackay, University of Glasgow, UK
Kevin Morgan, University of Hull, UK
Ben Mulcahy, University of Southampton, UK
Lucy Norling, Queen Mary, University of London, UK
Terence Pang, University of Melbourne, Australia
Nimesh Patel, Queen Mary, University of London, UK
Ryan Pelis, Dalhousie University, Canada
Victoria Ridger, University of Sheffield, UK
Bianca Rocca, Università Cattolica del Sacro Cuore, Italy
Liz Rosethorne, Novartis, UK
Pawan Sharma, University of Calgary, Canada
Douglas Sweet, Virginia Commonwealth University, USA
Jerome Swinny, University of Portsmouth, UK
Gareth Veal, Newcastle University, UK
Catriona Waitt, The University of Liverpool, UK
James Whiteford, Queen Mary, University of London, UK
Jeanette Wollard, University of Nottingham, UK
Tiantai Zhang, Peking Union Medical College, China

Pharmacology Research & Perspectives Launches at Experimental Biology 2013

Launch event - James E. Barrett, Chair of ASPET's Board of Publications Trustees; Michael J. Curtis, Editor-in-Chief; Graeme Henderson, Vice President - Publications (BPS); Darrell R. Abernethy, Deputy Editor

We are delighted that Pharmacology Research & Perspectives (PR&P) launched successfully at EB2013. 

PR&P is a new collaboration between the British Pharmacological Society (BPS) and the American Society for Pharmacology and Experimental Therapeutics (ASPET) and is supported by their prestigious journals.

Crowds at the PR&P launch enjoying the atmosphereThe journal was formally introduced at the ASPET Business Meeting which preceeded the launch reception. James Barrett, the Chair of ASPET’s Board of Publications Trustees introduced the Editor-in-Chief: Michael J. Curtis and advised the audience that the editors and society officers would be available to take questions about the journal at the reception. The ASPET/BPS Opening Reception then followed. PR&P banners were placed around the room including key information about the new journal, and BPS, ASPET and Wiley staff were on hand to distribute leaflets. Delegates enjoyed a steady supply of drinks and a buffet and the event was enjoyed by all. 

Throughout the conference there were a number of smaller events to introduce the journal: ‘Meet-the-editor’ events were held at the BPS and ASPET booths, giving potential authors the opportunity to discuss their paper and how to submit. The journal was also introduced at the ASPET Joint Editorial Boards Dinner, and delegates passed the PR&P banners as they went to sessions and meetings.

For more information about PR&P visit the journal’s website > 
or send an email to the editorial office >
Submit your paper via the journal’s online submission site >
Ensure you don’t miss any PR&P articles when they publish. Sign up for free e-toc alerts >

Official launch of journal Pharmacology Research & Perspectives at ASPET-BPS joint meeting

PRP2 short

Boston, MA — April 20, 2013—The American Society for Pharmacology and Experimental Therapeutics (ASPET), British Pharmacological Society (BPS) and John Wiley & Sons have issued a call for papers for their new open access, peer-reviewed journal, Pharmacology Research & Perspectives. The announcement was made as the three partners prepare for the official launch of the journal at the Joint ASPET-BPS Annual Meeting, taking place beginning April 20 as part of the Experimental Biology 2013 conference.

Pharmacology Research & Perspectives (PR&P) will publish original research, reviews and perspectives in all areas of preclinical and clinical pharmacology, therapeutics, education and related research areas. The journal will serve as the first fully open access journal for ASPET and BPS, and joins their combined portfolio of prestigious peer-reviewed subscription-based scientific journals, including Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, Molecular Pharmacology, British Journal of Pharmacology, and British Journal of Clinical Pharmacology.

 Editor-in-Chief Dr Michael J. Curtis commented, “I’m pleased to announce that Pharmacology Research & Perspectives is now open for submissions. ASPET, BPS and Wiley publish high-quality peer-reviewed journals – and our collaboration will continue this tradition.”

Dr Curtis obtained his PhD from the University of British Columbia and has been a Reader at King’s College London since 1996. Dr Curtis has extensive editorial experience, serving as Editor-in-Chief of the Journal of Pharmacological and Toxicological Methods and Reviews Editor of British Journal of Pharmacology, among other positions.

Dr Darrell Abernethy will join the new journal as Deputy Editor. Dr Abernethy’s faculty appointment is with the Johns Hopkins University School of Medicine. He received his MD (AOA) and PhD (Pharmacology) degrees from the University of Kansas School of Medicine. Dr Abernethy is an experienced editor, having served as Editor-in-Chief of Pharmacological Reviews and an Associate Editor of the Journal of Pharmacology and Experimental Therapeutics among other positions.

All articles in PR&P will be published as fully open access under a Creative Commons License on Wiley Online Library and deposited in PubMed Central immediately upon publication. A publication fee will be payable by authors on acceptance of their articles. Authors affiliated with, or funded by, an organization that has a Wiley Open Access Account can publish without directly paying any publication charges.

 The journal expects to publish its first issue in autumn 2013.

Darrell Abernethy MD, PhD appointed as Deputy Editor of Pharmacology Research & Perspectives (PR&P)

Abernethy_Darrell_cropped We are delighted to announce the appointment of Darrell Abernethy as Deputy Editor of Pharmacology Research & Perspectives (PR&P).  Darrell joins Editor-in-Chief, Michael J. Curtis of King’s College London, to direct the new open access, peer-reviewed journal that will open for submissions in April 2013. Dr. Abernethy’s faculty appointment is with the Johns Hopkins University School of Medicine. He received his M.D. (AOA) and Ph.D. (Pharmacology) degrees from the University of Kansas School of Medicine. Dr. Abernethy is an experienced editor. He served as Editor-in-Chief of Pharmacological Reviews and as an Associate Editor of the Journal of Pharmacology and Experimental Therapeutics among other positions. He has contributed to the understanding of mechanisms of peripheral distribution of drugs and drug disposition and effect in obesity. He is currently developing a pharmacology mechanism-based drug safety prediction program based on systems pharmacology.

prp_cover_final.indd PR&P will be published in partnership with Wiley, The American Society for Pharmacology and Experimental Therapeutics (ASPET) and the British Pharmacological Society (BPS).  PR&P will publish original research, reviews and perspectives in all areas of preclinical and clinical pharmacology, therapeutics, education and related research areas.  More information regarding the new journal can be read here.

ASPET and BPS Partner With Wiley To Launch Open Access Journal Pharmacology Research & Perspectives

prp_cover_final.inddThe American Society for Pharmacology and Experimental Therapeutics (ASPET) and the British Pharmacological Society (BPS) announced today their partnership to publish the new open access, peer-reviewed journal, Pharmacology Research & Perspectives, which will open for submissions in April 2013. Michael J. Curtis of King’s College London, UK has been appointed as Editor-in-Chief of this new journal.

Pharmacology Research & Perspectives (PR&P) will publish original research, reviews and perspectives in all areas of preclinical and clinical pharmacology, therapeutics, education and related research areas.  The journal will serve as the first fully open access journal for ASPET and BPS, and joins their combined portfolio of prestigious peer-reviewed subscription-based scientific journals, such as the Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, Molecular Pharmacology, British Journal of Pharmacology, and British Journal of Clinical Pharmacology.

MJC bestEditor-in-Chief Dr. Michael J. Curtis obtained his PhD from the University of British Columbia and has been a Reader at King’s College London since 1996. Dr Curtis has extensive editorial experience, serving as Editor-in-Chief of the Journal of Pharmacological and Toxicological Methods and Reviews Editor of British Journal of Pharmacology, among other positions.

“The publication of Pharmacology Research & Perspectives puts the ASPET-BPS-Wiley alliance at the forefront of open access publishing in pharmacology. I am confident that Mike’s expertise and insight will ensure we are able to realise the full potential of this exciting opportunity,” said Professor Philip Routledge, BPS President.

“ASPET is pleased to be working with the British Pharmacological Society and Wiley to launch this exciting new open access journal.  The journal builds on the long-standing excellence of the publications associated with the two scientific societies and we join enthusiastically with Wiley in this new endeavor that will provide additional options for scientists and a forum for new directions in the discipline of pharmacology,” commented James E. Barrett, Chair of ASPET’s Board of Publications Trustees.

Deborah Dixon, VP, Publishing Director, Wiley, added, “We are extremely pleased to be partnering with two prestigious organizations to publish this new open access journal in pharmacology. It will provide authors worldwide with a high quality publishing option that will be fast and efficient.”

All articles in PR&P will be published as fully open access under a Creative Commons License on Wiley Online Library and deposited in PubMed Central immediately upon publication. A publication fee will be payable by authors on acceptance of their articles. Authors affiliated with, or funded by, an organization that has a Wiley Open Access Account can publish without directly paying any publication charges.

 The journal expects to publish its first issue in autumn 2013.